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Overview ● Major takeaways from 2021 guidelines and differences from previous years
● Epidemiology, prevention strategies and glycemic 
targets
● Evolving use of technology in individualized DM 
management 
● Care for older adults
● Cardiovascular outcomes
● Updated treatment guidelines 
● Impact of guidelines 
What Will Not Be 
Discussed
Management of T1DM
Management of diabetes in children or 
pregnant patients 
Inpatient management of DM
Comorbidities (retinopathy, neuropathy)
HTN/ Lipid/ Aspirin Guidelines 
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Epidemiology >4000 new cases of DM in the United States per day 
>122 million Americans have DM or preDM
¼ of older adults have DM, and ½ have preDM
ADA Guidelines Developed by the ADA’s multidisciplinary Professional Practice Committee
Updated and published annually since 1989
Includes most current evidence based 
recommendations for diagnosis and management of 
DM
Includes 15 domains of DM
ADA Evidence Grading System 
Improving Care and 
Promoting Health in 
Populations
Outcomes 
● ½ of adult diabetics reported financial stress
● ⅕ reported food insecurity
2x risk of developing DM in those with food insecurity 
Higher risk of medication non adherence 
Prevention and Delay of T2DM
DM Classification LADA (Latent Autoimmune Diabetes in Adulthood)
● Autoimmune destruction of pancreatic beta cells 
● Adults have higher reserve of insulin secretory capacity than 
children 
● May or may not appear phenotypically like T2DM
● Most will become insulin deficient and will require insulin 
therapy sooner
Glycemic Targets A1c is now retitled “Glycemic Assessment”
Glycemic goals: 
1. A1c < 7% for most non pregnant adults A
2. Time in range >70%, with time below range <4% for those using 
continuous glucose monitoring (CGM) B
3. Less stringent A1C goals (A1c <8%) for pt with limited life 
expectancy, or when risk of ASE is greater than anticipated 
benefits B
Glycemic Targets ACCORD, ADVANCE, VADT Trials
Aim: 
Evaluate effect of intensive glucose control (A1c <6) on cardiac 
outcomes in patients with T2DM and CVD or cardiac risk factors 
Outcome: 
1. Lower A1c associated with reduced onset/ progression 
of microvascular complications 
2. Increased mortality in the intensive group in the ACCORD 
trial (HR1.22)
3. Increased rate of weight gain, severe hypoglycemia 
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Diabetes 
Technology 
No one size fits all approach 
Patient and provider interest and comfort highly 
variable 
Insurance coverage lags behind device availability 
May offer insight into impact of diet, exercise and 
medication management 
Can lower A1c when combined with structured 
medication titration
No effect on A1c when used alone
Self Monitored Blood 
Glucose (SMBG)  
Continuous Glucose Monitoring Help maintain A1c and reduce hypoglycemic episodes 
in patients on continuous insulin A, or other forms of 
subq insulin C
Do not need  to be on insulin therapy
Useful for medication titration 
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Older Adults >¼ of patients over 65 have DM, ½ are prediabetic 
Higher rates of premature death, functional disability, 
accelerated muscle loss, and coexisting illnesses, 
such as HTN, CAD, and stroke, than those without DM
Greater risk for geriatric syndromes (polypharmacy, 
cognitive impairment, depression, urinary 
incontinence, falls, persistent pain)
Older Adults Glycemic targets
● Healthy patients >65 with few coexisting chronic illness and 
intact cognition--> aim for A1c<7-7.5 C
● Medically complex/ poor overall health status→ avoid reliance 
on A1c, instead focus on avoiding hypoglycemia and 
symptomatic hyperglycemia C
Medication classes with low risk of hypoglycemia are 
preferred. B
Overtreatment of diabetes is common in older adults and 
should be avoided. B
Deintensify therapy to reduce hypoglycemia and 
polypharmacy if possible  B
Older Adults Consider CGM in older adults at risk of hypoglycemia (T1DM, insulin/sulfonylurea therapy)  A
Wireless Innovation in Seniors with Diabetes Mellitus 
(WISDM) trial 
● 2017-2019, 200 pt >60 years old with T1DM 
● Pt with T1DM randomized to CGM or standard glucose 
glucose monitoring 
● Over 6 months, CGM resulted statistically significant 
reduction in time spent in hypoglycemia compared to 
standard care
● Extrapolated - CGM may be an option for older patients with 
type 2 diabetes using multiple daily injections of insulin 
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CVD Risk Management Few major changes aside from more robust evidence supporting previous recommendations 
● AECi/ARB  for HTN
● Statin guidelines
● ASA therapy
● GLP-1 agonists and SGLT-2 inhibitors
Macrovascular/ CVD Outcomes In patients with T2DM who have established ASCVD 
or established kidney disease: 
● an SGLT2I or GLP-1RA is recommended as part of the 
comprehensive CV risk reduction and/or 
glucose-lowering regimens A
● a GLP-1RA is recommended to reduce the risk of major 
adverse cardiovascular events A
In patients with T2DM and HFrEF:
● An SGLT2 inhibitor is recommended to reduce risk of 
worsening HF and CV death. A





Consider initiating an SGLT2 Inhibitor in all patients 
with T2DM and evidence of diabetic kidney disease  A
GLP-1 receptor agonists slow progression of kidney 
disease in patients with CKD who are at higher risk of 
CV events A
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Metformin
Dual therapy Consider dual therapy when A1c> 8.5, or when A1c not at goal after 3 months on MFM monotherapy A
VERIFY TRIAL (2019 Lancet)
● 2001 patients, 18-70 yo with T2DM, A1c 6.5-7.0
● Early combination therapy with MFM+DPP-4 Vildagliptin 
vs standard therapy (MFM alone)
● Primary endpoint: time to treatment failure (two 
consecutive A1c>7)
● Outcome: initial combination therapy had overall slower 
decline in glycemic control 
Results have not proven to be generalizable 






1. Stimulate insulin production 
2. inhibition of glucagon secretion
3. inhibit gastric emptying 
4. Decrease appetite 
Benefits
● Reduce A1c by 1-2%
● 5-10lb wt loss
● Proven cardiovascular and renal benefits
Downsides
● Primarily injectables 
● Mainly GI upset
GLP-1 Agonists When compared to insulin
● Similar reduction in A1c
● Lower risk of hypoglycemia
● Beneficial effect on body weight 
● *more GI side effects
High costs and tolerability issues remain  barriers to 
widespread use
MOA
Inhibit sodium- glucose transporter in the proximal tubule→ 
decreased glucose reabsorption 
Benefits
● Do not lead to hypoglycemia 
● Reduce A1c 0.5-1.0%
● 4-6 lb wt loss, small reduction in blood pressure
● Significant cardiovascular and renal benefit 
ASE
● Hypovolemia
● GU/ yeast infections
● DKA






Glucose-lowering medication in type 2 diabetes: 
2021 ADA Professional Practice Committee 
adaptation of Davies MJ, D’Alessio DA, Fradkin J, et 
al. Diabetes Care 2018;41: 2669–2701 and Buse JB, 
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Financial Hardship
41 million Americans live below federal poverty line
28 million Americans did not have health insurance. 
Among the insured, 43% reported that they struggled 
to meet their deductible
¼ of adults reported difficulty affording medications
40% of Americans could not afford a $400 emergency.
Risk factors for difficulty affording medications
● Low income
● Poor health status
● Prescribed 4 or more medications
2021 editorial in the AMA Journal of Ethics  
Consequences of cost pathway
● Creates appearance of evidence based quality for inferior care
● Creation of social hierarchy
What do we do if financial hardship is identified? 
● Bias towards inferior care? 
● Physician burnout 
● Harm provider - patient relationship 
Professional ethics vs real world financial constraints 
Does a Cost 
Pathway Harm 
Patients? 
● Reviewed the major takeaways from 
2021 ADA guidelines and changes 
from previous years
● Discussed evolving use of 
technology in individualized DM 
management 
● Updated pharmacologic 
management 
● Societal impact of these changes 
Summary 
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● ASCVD risk <15% →  less than 140/90 A
● ASCVD risk>15% →  less than 130/80 C
First line agent should be ACEi/ ARB A
● Maximize these prior to initiating second agent if evidence of 
proteinuria
● not indicated for diabetic pts without evidence of HTN, CKD 
or proteinuria A
Those not controlled on three or more  medications should be 




● Almost 5000 patients with T2DM
● Randomized to standard BP goal (<140 SBP) or intensive 
goal (<120)
● Primary endpoint: nonfatal MI, stroke, death from CV 
events. 
● Results: 
a. Reduction in nonfatal stroke rate (HR 0.59)
b. Increased death from any cause (HR 1.07)
c. Increased rate of ASE (3.3% vs 1.3%)
Did not reduce the rate of a composite outcome of 
fatal and nonfatal major cardiovascular events.
Lipid Management All patients should undergo lifestyle modifications A
Primary Prevention
● Age 40–75 without ASCVD→ initiate moderate-intensity 
statin A
● Age 50-70 or with multiple ASCVD risk factors→ initiate 
high intensity statin B 
● Age 20-39 with ASCVD risk factors→ consider initiating 
statin therapy (does not specify intensity) C
● If ASCVD >20%→ consider ezetimibe in addition to max 
statin to reduce LDL by >50% C 
Lipid Management Secondary Prevention
● All patients should be on high intensity statin in addition 
to lifestyle mods A
● If LDL >70 and with other ASCVD risk factors→ consider 
additional LDL lowering agent (ezetimibe or PCSK9 
inhibitor). A
● For patients with DM and >75, if already on statin 
therapy, reasonable to continue statin B
2012 Meta-analysis of 13 RCT (91,140 participants) 
published in Lancet 
● OR 1.09 for a new diagnosis of diabetes
● On average, treatment of 255 patients with statins for 4 
years resulted in one additional case of diabetes 
● Statins simultaneously prevented 5.4 vascular events 
among those 255 patients
Diabetic Risk with 
Statin Use?
Aspirin Indicated as a secondary prevention strategy in those with diabetes and a history of ASCVD. A
Consider as primary prevention strategy in patients 
50-70yo with DM who are at increased CV risk, after 
discussion of risk/ benefit A
Not recommended for those at low risk of ASCVD, as 
the low benefit is likely to be outweighed by the risks 
of bleeding.
May offer insight into impact of diet, exercise and 
medication management 
Can lower A1c when combined with structured 
medication titration
No effect on A1c when used alone
Self Monitored Blood 
Glucose (SMBG)  
